ACADIA Pharmaceuticals, which is developing treatments for central nervous system and neurological disease, said this morning that it has received funding from Fast Forward LLC, a nonprofit established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck. ACADIA said the $545,000 from the two will go towards preclinical studies for its AC-186 compound, which is being approached as a new treatment of multiple sclerosis. ACADIA said the new funds will go towards research being conducted in collaboration with Dr. Rhonda Voskuhl of UCLA.